(Q37715703)

22 August 2017

1 reference

title

The safety and side effects of monoclonal antibodies (English)

1 reference

22 August 2017

1 reference

1 reference

1

Trevor T Hansel

1 reference

22 August 2017

Harald Kropshofer

2

1 reference

22 August 2017

Thomas Singer

series ordinal

3

1 reference

22 August 2017

Jane A Mitchell

series ordinal

4

1 reference

22 August 2017

Andrew J T George

series ordinal

5

1 reference

22 August 2017

22 March 2010

1 reference

Nature Reviews Drug Discovery

22 August 2017

1 reference

22 August 2017

9

1 reference

22 August 2017

325-338

1 reference

22 August 2017

4

1 reference

https://scigraph.springernature.com/pub.10.1038/nrd3003

22 August 2017

0 references

cites work

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

Paul Ehrlich's magic bullet concept: 100 years of progress.

31 March 2020

1 reference

Handbook of Therapeutic Antibodies

31 March 2020

1 reference

Human antibodies from transgenic animals

31 March 2020

1 reference

Monoclonal antibody successes in the clinic

31 March 2020

1 reference

Immunotherapy: past, present and future

31 March 2020

1 reference

Anti-infective monoclonal antibodies: perils and promise of development

31 March 2020

1 reference

Protein therapeutics: a summary and pharmacological classification

31 March 2020

1 reference

CAMPATH: from concept to clinic

31 March 2020

1 reference

Historical development of monoclonal antibody therapeutics

31 March 2020

1 reference

Molecular engineering and design of therapeutic antibodies

31 March 2020

1 reference

Therapeutic antibodies--delivering the promise?

31 March 2020

1 reference

Tumor necrosis factor antagonist mechanisms of action: a comprehensive review

31 March 2020

1 reference

31 March 2020

1 reference

European biologicals registers: methodology, selected results and perspectives

31 March 2020

1 reference

Getting specific: monoclonal antibodies in multiple sclerosis.

31 March 2020

1 reference

Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates

31 March 2020

1 reference

Biological half-life of normal and truncated human IgG3 in scid mice

31 March 2020

1 reference

Recombinant antibody therapeutics: the impact of glycosylation on mechanisms of action

31 March 2020

1 reference

Anti-neutrophil cytoplasm antibody IgG subclasses in Wegener's granulomatosis: a possible pathogenic role for the IgG4 subclass

31 March 2020

1 reference

Anti-Inflammatory Activity of Human IgG4 Antibodies by Dynamic Fab Arm Exchange

31 March 2020

1 reference

Preclinical and clinical safety of monoclonal antibodies

31 March 2020

1 reference

How do we assure the quality of biological medicines?

31 March 2020

1 reference

Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment.

31 March 2020

1 reference

Preclinical safety testing of monoclonal antibodies: the significance of species relevance.

31 March 2020

1 reference

Engineering of therapeutic antibodies to minimize immunogenicity and optimize function

31 March 2020

1 reference

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy

31 March 2020

1 reference

Adverse effects of the humanized antibodies used as cancer therapeutics

31 March 2020

1 reference

Management and preparedness for infusion and hypersensitivity reactions

31 March 2020

1 reference

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

31 March 2020

1 reference

Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose

31 March 2020

1 reference

IgE in allergy and asthma today

31 March 2020

1 reference

American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis

31 March 2020

1 reference

Safety and tolerability of omalizumab

31 March 2020

1 reference

How safe are the biologicals in treating asthma and rhinitis?

31 March 2020

1 reference

Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma

31 March 2020

1 reference

Improving the efficacy of antibody-based cancer therapies

31 March 2020

1 reference

The utility of monoclonal antibody therapy in renal transplantation

31 March 2020

1 reference

OKT3 first-dose reaction: association with T cell subsets and cytokine release

31 March 2020

1 reference

Molecular, biologic, and pharmacokinetic properties of monoclonal antibodies: impact of these parameters on early clinical development

31 March 2020

1 reference

Potent antibody therapeutics by design

31 March 2020

1 reference

Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies

31 March 2020

1 reference

Antibody humanization: a case of the 'Emperor's new clothes'?

31 March 2020

1 reference

Natalizumab for multiple sclerosis

31 March 2020

1 reference

The implications of immunogenicity for protein-based multiple sclerosis therapies

31 March 2020

1 reference

Factors influencing the immunogenicity of therapeutic proteins

31 March 2020

1 reference

Scientific and regulatory considerations on the immunogenicity of biologics

31 March 2020

1 reference

Immunogenicity of anti-tumor necrosis factor antibodies-toward improved methods of anti-antibody measurement

31 March 2020

1 reference

Guidelines for the management of pediatric and adult tumor lysis syndrome: an evidence-based review

31 March 2020

1 reference

Consensus conference on the management of tumor lysis syndrome

31 March 2020

1 reference

Acute tumor lysis syndrome after rituximab administration in Burkitt's lymphoma

31 March 2020

1 reference

Management of tumor lysis syndrome: need for evidence-based guidelines

31 March 2020

1 reference

Anti-TNF biologic agents: still the therapy of choice for rheumatoid arthritis

31 March 2020

1 reference

Role of cytokines in rheumatoid arthritis: an education in pathophysiology and therapeutics

31 March 2020

1 reference

Drug insight: tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis

31 March 2020

1 reference

TNF-blocking agents and tuberculosis: new drugs illuminate an old topic

31 March 2020

1 reference

Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden

31 March 2020

1 reference

Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials

31 March 2020

1 reference

Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis

31 March 2020

1 reference

Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease

31 March 2020

1 reference

The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients

31 March 2020

1 reference

BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies

31 March 2020

1 reference

Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a Review from the Research on Adverse Drug Events and Reports (RADAR) Project

31 March 2020

1 reference

Novel therapeutic strategies for multiple sclerosis--a multifaceted adversary

31 March 2020

1 reference

JCV detection in multiple sclerosis patients treated with natalizumab

31 March 2020

1 reference

Reemergence of PML in natalizumab-treated patients--new cases, same concerns

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy in a patient treated with natalizumab

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease

31 March 2020

1 reference

Treatment of progressive multifocal leukoencephalopathy associated with natalizumab.

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy after natalizumab monotherapy.

31 March 2020

1 reference

Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy

31 March 2020

1 reference

Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring

31 March 2020

1 reference

Natalizumab and PML: a risky business?

31 March 2020

1 reference

False negative PCR despite high levels of JC virus DNA in spinal fluid: Implications for diagnostic testing

31 March 2020

1 reference

Asymptomatic reactivation of JC virus in patients treated with natalizumab

31 March 2020

1 reference

Application of molecular tools for the diagnosis of central nervous system infections

31 March 2020

1 reference

Therapy: Targeted but not trouble-free: efalizumab and PML

31 March 2020

1 reference

Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab.

31 March 2020

1 reference

The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans

31 March 2020

1 reference

31 March 2020

1 reference

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

31 March 2020

1 reference

Drug-induced immune thrombocytopenia

31 March 2020

1 reference

Platelet GPIIb-IIIa blockers

31 March 2020

1 reference

Abciximab readministration: results of the ReoPro Readministration Registry

31 March 2020

1 reference

Multi-year follow-up of abciximab therapy in three randomized, placebo-controlled trials of percutaneous coronary revascularization

31 March 2020

1 reference

The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice

31 March 2020

1 reference

Delayed thrombocytopenia after treatment with abciximab: a distinct clinical entity associated with the immune response to the drug.

31 March 2020

1 reference

Thrombocytopenia after second exposure to abciximab is caused by antibodies that recognize abciximab-coated platelets

31 March 2020

1 reference

Glycoprotein IIb/IIIa receptor inhibitors in 2008: do they still have a role?

31 March 2020

1 reference

Lymphocyte homeostasis following therapeutic lymphocyte depletion in multiple sclerosis.

31 March 2020

1 reference

Morbidity and mortality in rheumatoid arthritis patients with prolonged therapy-induced lymphopenia: twelve-year outcomes

31 March 2020

1 reference

T-cell depletion with Campath-1H 'in the bag' for matched related allogeneic peripheral blood stem cell transplantation is associated with reduced graft-versus-host disease, rapid immune constitution and improved survival

31 March 2020

1 reference

CD52 antibodies for prevention of graft-versus-host disease and graft rejection following transplantation of allogeneic peripheral blood stem cells

31 March 2020

1 reference

Novel agents in chronic lymphocytic leukemia: efficacy and tolerability of new therapies

31 March 2020

1 reference

Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation--efficacy and safety at five years.

31 March 2020

1 reference

Alemtuzumab vs. interferon beta-1a in early multiple sclerosis

31 March 2020

1 reference

Multiple lessons for multiple sclerosis

31 March 2020

1 reference

Fatal thrombocytopaenia temporally related to the administration of alemtuzumab (MabCampath) for refractory CLL despite early discontinuation of therapy

31 March 2020

1 reference

Severe and prolonged myeloid haematopoietic toxicity with myelodysplastic features following alemtuzumab therapy in patients with peripheral T-cell lymphoproliferative disorders

31 March 2020

1 reference

The effect of anti-CD40 ligand in immune thrombocytopenic purpura

31 March 2020

1 reference

Thrombophilia associated with anti-CD154 monoclonal antibody treatment and its prophylaxis in nonhuman primates

31 March 2020

1 reference

Thromboembolic complications after treatment with monoclonal antibody against CD40 ligand

31 March 2020

1 reference

Platelet pro-aggregatory effects of CD40L monoclonal antibody

31 March 2020

1 reference

The role of CD40 in CD40L- and antibody-mediated platelet activation

31 March 2020

1 reference

Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab

31 March 2020

1 reference

Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis

31 March 2020

1 reference

Drug insight: autoimmune effects of medications-what's new?

31 March 2020

1 reference

Autoimmune Diseases Induced by TNF-Targeted Therapies

31 March 2020

1 reference

Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis

31 March 2020

1 reference

Anti-cytotoxic T-lymphocyte antigen-4 antibody: the first in an emerging class of immunomodulatory antibodies for cancer treatment

31 March 2020

1 reference

Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade

31 March 2020

1 reference

Principles and use of anti-CTLA4 antibody in human cancer immunotherapy

31 March 2020

1 reference

Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events

31 March 2020

1 reference

Is tumor immunity the same thing as autoimmunity? Implications for cancer immunotherapy

31 March 2020

1 reference

Malignancy and biologic therapy in rheumatoid arthritis

31 March 2020

1 reference

Tumor necrosis factor inhibitors for rheumatoid arthritis

31 March 2020

1 reference

Is there an association between anti-TNF monoclonal antibody therapy in rheumatoid arthritis and risk of malignancy and serious infection? Commentary on the meta-analysis by Bongartz et al

31 March 2020

1 reference

Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists

31 March 2020

1 reference

Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis

31 March 2020

1 reference

Treatment with biologic therapies and the risk of cancer in patients with IBD.

31 March 2020

1 reference

The safety and efficacy of infliximab in moderate to severe chronic obstructive pulmonary disease

31 March 2020

1 reference

Hepatosplenic T-cell lymphoma in adolescents and young adults with Crohn's disease: a cautionary tale?

31 March 2020

1 reference

A human interleukin-12/23 monoclonal antibody for the treatment of psoriasis

31 March 2020

1 reference

Current directions in IBD therapy: what goals are feasible with biological modifiers?

31 March 2020

1 reference

Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, dose-ranging study

31 March 2020

1 reference

Immunotherapy of cancer by IL-12-based cytokine combinations

31 March 2020

1 reference

IL-23 promotes tumour incidence and growth

31 March 2020

1 reference

Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan

31 March 2020

1 reference

Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer

31 March 2020

1 reference

Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?

31 March 2020

1 reference

Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker

31 March 2020

1 reference

Correlation between rash and a positive drug response associated with bevacizumab in a patient with advanced colorectal cancer

31 March 2020

1 reference

Completeness in the reporting of dermatologic adverse drug reactions associated with monoclonal antibody epidermal growth factor receptor inhibitors in phase II and III colorectal cancer clinical trials

31 March 2020

1 reference

Consensus guidelines for the management of radiation dermatitis and coexisting acne-like rash in patients receiving radiotherapy plus EGFR inhibitors for the treatment of squamous cell carcinoma of the head and neck

31 March 2020

1 reference

Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption

31 March 2020

1 reference

Trastuzumab--mechanism of action and use in clinical practice

31 March 2020

1 reference

Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition

31 March 2020

1 reference

Trastuzumab-induced cardiomyopathy.

31 March 2020

1 reference

Trastuzumab and cardiac dysfunction: update on preclinical studies

31 March 2020

1 reference

Herceptin and the heart--a molecular modifier of cardiac failure

31 March 2020

1 reference

Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer

31 March 2020

1 reference

Cardiotoxicity of the new cancer therapeutics--mechanisms of, and approaches to, the problem

31 March 2020

1 reference

Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics

31 March 2020

1 reference

ErbB2 is essential in the prevention of dilated cardiomyopathy.

31 March 2020

1 reference

Neuregulin activates erbB2-dependent src/FAK signaling and cytoskeletal remodeling in isolated adult rat cardiac myocytes

31 March 2020

1 reference

Inhibition of ErbB2 causes mitochondrial dysfunction in cardiomyocytes: implications for herceptin-induced cardiomyopathy

31 March 2020

1 reference

The advent of the cytokine storm.

31 March 2020

1 reference

Monoclonal antibody first dose cytokine release syndromes-mechanisms and prediction

31 March 2020

1 reference

A phase I study of visilizumab, a humanized anti-CD3 monoclonal antibody, in severe steroid-refractory ulcerative colitis

31 March 2020

1 reference

Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells

31 March 2020

1 reference

Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412

31 March 2020

1 reference

Establishing risk of human experimentation with drugs: lessons from TGN1412.

31 March 2020

1 reference

The minimum anticipated biological effect level (MABEL) for selection of first human dose in clinical trials with monoclonal antibodies

31 March 2020

1 reference

Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitis

31 March 2020

1 reference

CD28 superagonists: mode of action and therapeutic potential

31 March 2020

1 reference

A CD28 superagonistic antibody elicits 2 functionally distinct waves of T cell activation in rats

31 March 2020

1 reference

Manipulation of regulatory T-cell number and function with CD28-specific monoclonal antibodies

31 March 2020

1 reference

CD28 superagonists: what makes the difference in humans?

31 March 2020

1 reference

T cell-directed therapies: lessons learned and future prospects

31 March 2020

1 reference

T-cell costimulation--biology, therapeutic potential, and challenges

31 March 2020

1 reference

Preparing for first-in-man studies: the challenges for translational immunology post-TGN1412.

31 March 2020

1 reference

The calm after the cytokine storm: lessons from the TGN1412 trial

31 March 2020

1 reference

31 March 2020

Lessons from TGN1412.

1 reference

31 March 2020

1 reference

Signaling signatures and functional properties of anti-human CD28 superagonistic antibodies

31 March 2020

1 reference

Some aspects of the recombinantly expressed humanised superagonist anti-CD28 mAb, TGN1412 trial catastrophe lessons to safeguard mAbs and vaccine trials.

31 March 2020

1 reference

Dynamic regulation of T-cell costimulation through TCR-CD28 microclusters

31 March 2020

1 reference

Humanized IgG1 and IgG4 anti-CD4 monoclonal antibodies: effects on lymphocytes in the blood, lymph nodes, and renal allografts in cynomolgus monkeys

31 March 2020

1 reference

A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing

31 March 2020

1 reference

Loss of Siglec expression on T lymphocytes during human evolution

31 March 2020

1 reference

A therapeutic human IgG4 monoclonal antibody that depletes target cells in humans

31 March 2020

1 reference

Negative regulation of leucocyte functions by CD33-related siglecs

31 March 2020

1 reference

Siglecs and their roles in the immune system

31 March 2020

1 reference

Siglecs as positive and negative regulators of the immune system

31 March 2020

1 reference

Rapid regulatory T-cell response prevents cytokine storm in CD28 superagonist treated mice

31 March 2020

1 reference

Lethal effect of CD3-specific antibody in mice deficient in TGF-beta1 by uncontrolled flu-like syndrome

31 March 2020

1 reference

Safety assessment and dose selection for first-in-human clinical trials with immunomodulatory monoclonal antibodies

31 March 2020

1 reference

The utility of microdosing over the past 5 years

31 March 2020

1 reference

Safety of phase I clinical trials with monoclonal antibodies in Germany--the regulatory requirements viewed in the aftermath of the TGN1412 disaster

31 March 2020

1 reference

Symposium report--development of safe protein therapeutics: pre-clinical, clinical and regulatory issues

31 March 2020

1 reference

"Cytokine storm" in the phase I trial of monoclonal antibody TGN1412: better understanding the causes to improve preclinical testing of immunotherapeutics

31 March 2020

1 reference

Improved in vitro methods to predict the in vivo toxicity in man of therapeutic monoclonal antibodies including TGN1412

31 March 2020

1 reference

Molecular imaging in drug development

31 March 2020

1 reference

Microscopic imaging techniques for drug discovery

31 March 2020

1 reference

Superagonistic anti-CD28 antibodies: potent activators of regulatory T cells for the therapy of autoimmune diseases

31 March 2020

1 reference

12 December 2020

Ex-vivo whole blood cultures for predicting cytokine-release syndrome: dependence on target antigen and antibody isotype

1 reference

12 December 2020

Serum sickness following treatment with rituximab.

1 reference

12 December 2020

Fatal delayed thrombocytopenia following abciximab therapy

1 reference

12 December 2020

Musculoskeletal manifestations and autoimmune diseases related to new biologic agents

1 reference

12 December 2020

Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDEC-C2B8).

1 reference

12 December 2020

Developing antibodies for targeting immunoglobulin and membrane-bound immunoglobulin E.

1 reference

12 December 2020

Activation and increased expression of adhesion molecules on peripheral blood lymphocytes is a mechanism for the immediate lymphocytopenia after administration of OKT3

1 reference

12 December 2020

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

1 reference

12 December 2020

Targeting the IgE molecule in allergic and asthmatic diseases: review of the IgE molecule and clinical efficacy

1 reference

12 December 2020

Will immunogenicity limit the use, efficacy, and future development of therapeutic monoclonal antibodies?

1 reference

12 December 2020

Neuregulin-1 and its potential role in the control of cardiac function

1 reference

12 December 2020

Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma.

1 reference

12 December 2020

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3003

1 reference

Dimensions Publication ID

22 August 2017

0 references

1 reference